NCT03555422Phase 3Completed

Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

Study sponsor: Karyopharm Therapeutics Inc · KPTI

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2022-01-22Actual

Enrollment · participants263Actual

Source updated2026-04-13Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-04-13 · 1 field changed

Recruitment status changed

− Before

~~Active not recruiting~~

+ After

Completed

Check registry source

Study details

Conditions studied

Endometrial Cancer

Treatments or interventions studied

SelinexorDrug
Matching placebo for selinexorDrug

Primary outcomes · main study measures

measure: Progression Free Survival (PFS); description: Compare progression free survival of the two treatment arms as assessed by the investigator, per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.; timeFrame: Time from randomization until disease progression (PD) or death, whichever occurs first (approximately 12 months after the last participant enrolled)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history